Saham Philip Morris tampak sepenuhnya bernilai berdasarkan dividen

Saham Philip Morris International telah naik lebih dari 15% dalam dua bulan, kini diperdagangkan di atas $186 dan melampaui estimasi nilai wajar sebelumnya. Model diskon dividen terbaru dari seorang analis menunjukkan bahwa saham tersebut sudah sepenuhnya bernilai dengan potensi kenaikan terbatas dari harga saat ini. Penilaian ulang ini menyusul hasil pendapatan di bawah ekspektasi baru-baru ini dan kenaikan harga saham yang cepat.

Philip Morris International Inc. (PM), pemain utama di sektor tembakau dan produk bebas asap, telah mengalami lonjakan saham lebih dari 15% selama dua bulan terakhir. Saham tersebut kini diperdagangkan di atas $186, melampaui penilaian nilai wajar sebelumnya. Sebelumnya, pertumbuhan dividen yang kuat perusahaan dan ekspansi di produk bebas asap berkontribusi pada persepsi undervaluation, yang mendukung rating Buy. Namun, hasil pendapatan di bawah ekspektasi baru-baru ini dan kenaikan cepat harga saham telah memicu penilaian ulang fundamental. Seorang analis yang memulai liputan PM pada April 2023 dengan rating netral awal baru-baru ini menaikkan menjadi Buy. Menggunakan laba terbaru dalam model diskon dividen yang diperbarui, analis menyimpulkan bahwa saham kini sudah sepenuhnya bernilai, menawarkan potensi kenaikan lebih lanjut yang terbatas pada tingkat saat ini. Analisis menekankan bahwa meskipun kinerja dividen PM tetap kuat, apresiasi harga baru-baru ini mungkin tidak lagi membenarkan optimisme sebelumnya. Analis tidak memegang posisi di PM dan menyatakan opini pribadi tanpa kompensasi selain kontribusi Seeking Alpha. Perspektif ini menyoroti perlunya investor mempertimbangkan apakah pertumbuhan perusahaan di segmen bebas asap terus mendukung valuasinya di tengah pergeseran pasar.

Artikel Terkait

Split-scene illustration of BSE trading floor showing high-priced stocks' divergent FY26 performance: laggards crashing amid global tensions, gainers surging.
Gambar dihasilkan oleh AI

High-priced BSE stocks diverge in FY26 performance

Dilaporkan oleh AI Gambar dihasilkan oleh AI

Among 68 high-priced stocks trading above Rs 5,000 on the BSE, FY26 has brought more declines than gains amid global uncertainty and geopolitical tensions. The top six laggards fell 25-40%, while top gainers surged 40-130%. Institutional holdings vary across these stocks.

An analyst has downgraded Imperial Brands (IMBBY) stock to 'Hold' after significant gains. The stock delivered a 57.43% total return since initial coverage, outperforming the NASDAQ and tobacco peers. At current valuations, the margin of safety has diminished.

Dilaporkan oleh AI

Millicom International Cellular reported robust 2025 performance with margin expansion and strong free cash flow, according to an analyst review. However, rising leverage and integration risks into 2026 prompt a cautious outlook. The analyst raised the fair value estimate but maintained a hold recommendation due to limited upside.

Insiders at ZIM Integrated Shipping (NYSE:ZIM), including the CEO, have sold large portions of their holdings below a $35 per share takeover offer from Hapag-Lloyd. The stock initially surged on the news but now shows technical weakness. Analysts cite political and regulatory hurdles as risks to the deal.

Dilaporkan oleh AI

Shares of Solventum (NYSE:SOLV) have been trading sideways following its spin-off from its former parent company, as investors assess separation impacts and stranded costs. Despite a $4.1 billion divestment and $500 million in targeted cost savings, the company's 2025 results showed minimal free cash flow and modest earnings growth. For 2026, guidance projects 2-3% organic sales growth and adjusted EPS of $6.50, though free cash flow is expected to remain weak at around $200 million.

A Seeking Alpha analyst has rated PayPal Holdings (NASDAQ:PYPL) as Sell with a 12-month price target of $59. The rating cites a lack of catalysts for re-rating despite cheap valuation, driven by stagnating core revenue and aggressive buybacks. FY26 guidance anticipates EPS declines, the first since the eBay separation.

Dilaporkan oleh AI

A Seeking Alpha analyst has upgraded TransMedics (NASDAQ:TMDX) to Strong Buy, citing expected revenue growth of around 25% in 2026 and free cash flow breakeven by late 2026 or early 2027. The firm is seen as over the peak of its capital expenditure cycle, with margins targeting 30% by 2028. The analyst holds a long position in the stock.

 

 

 

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak